Table 2.
Baseline characteristics of the participants
| Study ID | Age (years) mean (SD) | Gender (female) N (%) | BMI, mean (SD) | RF positive, N (%) | Anti-CCP positive, N (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OKZ | PBO | OKZ | PBO | OKZ | PBO | OKZ | PBO | OKZ | PBO | ||||||
| q2w | q4w | q2w | q4w | q2w | q4w | q2w | q4w | q2w | q4w | ||||||
| Feist et al. 2022 [19] | 53.4 (12.7) | 53.9 (11.7) | 53.0 (13.7) | 122 (88.4) | 130 (80.7) | 55 (79.7) | 28.8 (7.0); | 29.2 (6.0) | 28.4 (5.6) | 105 (76.1) | 128 (79.5) | 55 (79.7) | 96 (69.6) | 124 (77.0) | 58 (84.1) |
| Genovese et al. 2014 [15] | 60 mg: 55.5; 120 mg: 53.1; 240 mg: 55.5 | 60 mg: 52.64; 120 mg: 53.52; 240 mg: 54.55 | Q2W: 59.63; Q4W: 58.18 | 60 mg: 16 (80); 120 mg: 19 (86.4); 240 mg: 21 (91.3) | 60 mg: 20 (90.9); 120 mg: 20 (87); 240 mg: 17 (77.3) |
Q2W: 19 (86.4) Q4W: 17 (77.3) |
N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Nasonov et al. 2021 [18] | 52.0 (11.8) | 49.1 (12.1) | 52.7 (11.3) | 116 (81.1) | 118 (83.1) | 120 (83.9) | 26.6 (5.1) | 26.4 (5.5) | 26.9 (5.0) | 115 (80.4) | 122 (85.9) | 127 (88.8) | 110 (76.9) | 115 (81.0) | 117 (81.8) |
| Smolen et al. 2022 [17] | 53.3 (11.9) | 53.7 (12.1) | 54.7 (11.9) | 352 (75.9) | 378 (78.9) | 190 (78.2) | 28.7 (6.1) | 28.7 (6.3) | 28.6 (6.6) | 352 (75.9) | 355 (74.1) | 181 (74.5) | 355 (76.5) | 361 (75.4) | 188 (77.4) |
| Takeuchi et al. 2016 [16] | N/A | 60 mg: 53.9 (10.6); 120 mg: 55.7 (10.8); 240 mg: 56.7 (11.0) | 52.6 (11.3) | N/A | 60 mg: 31 (96.6); 120 mg: 26 (81.3); 240 mg: 21 (80.8) | 25 (86.2) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Study ID | DAS28-CRP, mean (SD) | CDAI score, mean (SD) | HAQ-DI score, mean (SD) | TJC, mean (SD) | SJC, mean (SD) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OKZ | PBO | OKZ | PBO | OKZ | PBO | OKZ | PBO | OKZ | PBO | ||||||
| q2w | q4w | q2w | q4w | q2w | q4w | q2w | q4w | q2w | q4w | ||||||
| Feist et al. 2022 [19] | 5.9 (0.9) | 6.0 (0.8) | 6.2 (0.9) | 40.7 (12.5) | 41.7 (10.6) | 44.4 (11.7) | 1.8 (0.6) | 1.8 (0.6) | 1.8 (0.6) | 26.0 (13.7) | 25.6 (12.8) | 28.2 (13.7) | 16.8 (8.2) | 17.0 (7.8) | 19.3 (9.5) |
| Genovese et al. 2014 [15] | 60 mg: 5.57; 120 mg: 5.96; 240 mg: 5.94 | 60 mg: 6.14; 120 mg: 5.61; 240 mg: 5.83 | q2W: 5.53; Q4W: 5.69 | 60 mg: 40.27 (11);120 mg: 44.5 (12.9); 240 mg: 43.2 (11.55) | 60 mg: 46 (12); 120 mg: 38.5 (11.35); 240 mg: 41.1 (8.75) | Q2W: 37.1 (8.3); Q4W: 37.9 (10.25) | 60 mg: 1.5 (0.4); 120 mg: 1.62 (0.6); 240 mg: 1.8 (0.5) | 60 mg: 1.7 (0.7); 120 mg: 1.55 (0.65); 240 mg: 1.55 (0.7) | Q2W: 1.5 (0.58); Q4W: 1.29 (0.6) | 60 mg: 28.5 (14.75); 120 mg: 30.75 (13.5); 240 mg: 30.75 (11.25) | 60 mg: 37.25 (14.75); 120 mg: 30.65 (12.5); 240 mg: 30.36 (12.2) | Q2W: 32.9 (11.85); Q4W: 27.5 (12.5) | 60 mg: 22.25 (11); 120 mg: 23.25 (13); 240 mg: 21.85 (8.65) | 60 mg: 26.75 (13); 120 mg: 17 (7.8); 240 mg: 18.5 (8.23) | Q2W: 15 (6); Q4W: 18.76 (10.18) |
| Nasonov et al. 2021 [18] | 6.0 (0.7) | 5.9 (0.7) | 6.0 (0.8) | 40.5 (9.8) | 38.7 (9.4) | 40.4 (10.5) | 1.74 (0.47) | 1.64 (0.50) | 1.78 (0.49) | 24.4 (11.4) | 22.2 (10.3) | 24.0 (11.3) |
14.8 (6.5) O |
14.5 (6.7) | 14.6 (6.9) |
| Smolen et al. 2022 [17] | 5.9 (0.8) | 5.8 (0.8) | 5.8 (0.8) | 39.4 (11.0) | 39.4 (11.3) | 38.7 (11.4) | 1.73 (0.58) | 1.69 (0.60) | 1.71 (0.62) | 23.9 (12.5) | 23.6 (12.9) | 22.4 (12.3) | 14.6 (7.3) | 15.4 (8.8) | 14.9 (8.5) |
| Takeuchi et al. 2016 [16] | N/A | 60 mg: 5.5 (0.925); 120 mg: 5.2 (0.875);240 mg: 5.3 (0.75) | 5.4 (1.05) | N/A | 60 mg: 39.35 (15.3); 120 mg: 27.3 (8.65); 240 mg: 29.8 (6.925) | 35.6 (11.45) | N/A | 60 mg: 1.19 (0.7); 120 mg: 1.25 (0.75); 240 mg: 0.88 (0.575) | 1.13 (0.6) | N/A | 60 mg: 14.5 (15.5); 120 mg: 12.5 (11.75); 240 mg: 13 (7.25) | 16 (9.25) | N/A | 60 mg: 12.5 (9); 120 mg: 10 (5.25); 240 mg: 12 (6.25) | 12 (9.25) |
OKZ, olokizumab; PBO, placebo; q2w, every 2 weeks; q4w, every 4 weeks; BMI, basal metabolic index; RF, rheumatoid factor; CCP. cyclic citrullinated peptide; DAS28-CRP, disease activity score 28 based on C-reactive protein; HAQ-DI, health assessment questionnaire disability index; CDAI, clinical disease activity index score; SJC, swollen joint count; TJ, tender joint count; N, number; SD, standard deviation; N/A, not available